Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.

@article{Golfier2014AnetumabRA,
  title={Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.},
  author={Sven Golfier and Charlotte C. Kopitz and Antje Kahnert and Iring Heisler and Christoph A. Schatz and Beatrix Stelte-Ludwig and Anke Mayer-Bartschmid and Kerstin Unterschemmann and Sandra Bruder and Lars Linden and Axel Harrenga and Peter Hauff and Frank Scholle and Beate M{\"u}ller-Tiemann and Bertolt Kreft and Karl Ziegelbauer},
  journal={Molecular cancer therapeutics},
  year={2014},
  volume={13 6},
  pages={
          1537-48
        }
}
Mesothelin is a tumor differentiation antigen frequently overexpressed in tumors such as mesothelioma, ovarian, pancreatic, and lung adenocarcinomas while showing limited expression in nonmalignant tissues. Mesothelin is therefore an attractive target for cancer therapy using antibody-drug conjugates (ADC). This study describes the detailed characterization of anetumab ravtansine, here referred to as BAY 94-9343, a novel ADC consisting of a human anti-mesothelin antibody conjugated to the… CONTINUE READING
Tweets
This paper has been referenced on Twitter 7 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 39 CITATIONS, ESTIMATED 64% COVERAGE

61 Citations

01020'14'15'16'17'18'19
Citations per Year
Semantic Scholar estimates that this publication has 61 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
SHOWING 1-10 OF 44 REFERENCES

Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 throughMAPK/ERKand JNKpathways

  • MC Chang, CA Chen, PJ Chen, YC Chiang, YL Chen, TL Mao
  • BiochemJ
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…